Hypomethylating agents plus venetoclax versus intensive chemotherapy prior to transplant in high-risk acute myeloid leukemia
Maël Heiblig, Kelly Ling, Eric S. Winer, Maximilian Stahl et al.
Journal
Haematologica
Topics
Acute Myeloid Leukemia Research
article
Hypomethylating agents plus venetoclax versus intensive chemotherapy prior to transplant in high-risk acute myeloid leukemia
Maël Heiblig, Kelly Ling, Eric S. Winer, Maximilian Stahl, Nikolai Alexandrovich Podoltsev, Luis E. Aguirre, Marlise Rachael Luskin, Urbain Tauveron-Jalenques, Sylvain Garciaz, Guillaume Berton, Julia Gilhodes, Martha Wadleigh, Shai O. Shimony, Rebecca P. Bystrom, Andrius Žučenka, Aaron D. Goldberg, Amel Soua, Alexandre Iat, Leora Boussi, Lourdes Mendez, Jan Philipp Bewersdorf, Luca Lanino, Rory Michael Shallis, Eytan M. Stein, Evan C. Chen, Edouard Forcade, Thomas Cluzeau, Daniel J. DeAngelo, Richard M. Stone, Amer M. Zeidan, Jacqueline S. Garcia, Pierre-Yves Dumas, Raynier Devillier
article en
Abstract
No abstract available for this paper.
Publication Tag
Haematologica
Institutions
Memorial Sloan Kettering Cancer Center (US), Université de Bordeaux (FR), Inserm (FR), Vilnius University (LT), Aix-Marseille Université (FR), Centre Hospitalier Universitaire de Bordeaux (FR), Centre Hospitalier Universitaire de Nice (FR), Moffitt Cancer Center (US), Yale University (US), Hospices Civils de Lyon (FR), Dana-Farber Cancer Institute (US), Duke Medical Center (US), Centre Hospitalier Universitaire de Clermont-Ferrand (FR), Centre de Recherche en Cancérologie de Marseille (FR), Institut Paoli-Calmettes (FR)
Funders
Bristol-Myers Squibb, Jazz Pharmaceuticals, Syndax Pharmaceuticals, Daiichi-Sankyo, Astellas Pharma, Servier, Swedish Orphan Biovitrum, Genentech